BioInvent To Cut Jobs By A Quarter Following Head-To-Head Clinical Trial Disappointment
This article was originally published in The Pink Sheet Daily
Executive Summary
Sweden's antibody platform company BioInvent moves quickly to reorganize following disappointing Phase IIb clinical results with a potential antithrombotic antibody.
You may also be interested in...
BioInvent's Tie-Up With Cancer Research Technology Brings Some Relief From Pipeline Setbacks
Sweden's BioInvent forges links with researchers at Queen Mary, University of London, and Cancer Research Technology, the commercial arm of charity Cancer Research UK, to identify new therapeutic antibodies for oncology.
Ablynx: Balancing Partners And Pipeline
Next-generation antibody company Ablynx boasts a series of technology partnership deals but its primary goal is to develop drugs. Can partners’ money fund a pipeline with sufficient focus to be manageable, but enough breadth to survive?
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.